Cadence Pharmaceuticals, Inc. (CADX) Misses Q1 EPS by 5c; Guides Q2 Sales Below

Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.93 million.

Sees Q2 2012 revenue of $10-$10.4 million, versus the consensus of $15.0 million.

For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Optimum Communications gets NYSE non-compliance notice over stock price